Loading...
•
Jun 30
TELA Bio Q2 2025 Earnings Report
TELA Bio reported its financial results for the second quarter ended June 30, 2025, showing significant revenue growth and improved profitability compared to the prior year period.
Key Takeaways
TELA Bio delivered strong second-quarter 2025 financial results, with revenue reaching $20.2 million, a 26% increase year-over-year. The company also significantly reduced its net loss and loss from operations, demonstrating improved financial performance. Increased demand for OviTex® and OviTex PRS products, along with strategic commercial leadership appointments and European market expansion, contributed to this growth.
Revenue for Q2 2025 was $20.2 million, marking a 26% increase over Q2 2024 and 9% sequential growth from Q1 2025.
Gross profit increased to $14.1 million, representing 69.8% of revenue, up from 68.8% in Q2 2024, primarily due to a lower charge for excess and obsolete inventory.
Net loss significantly improved to $9.9 million in Q2 2025, compared to a net loss of $12.6 million in Q2 2024.
The company reiterated its full-year 2025 revenue guidance of $85.0 million to $88.0 million, indicating continued expected growth of 23% to 27% over 2024.
TELA Bio
TELA Bio
Forward Guidance
TELA Bio reiterated its full-year 2025 revenue guidance, projecting continued strong growth.
Positive Outlook
- Full year 2025 revenue is projected to range from $85.0 million to $88.0 million.
- This represents a growth of 23% to 27% over full year 2024.
- The company is strengthening commercial leadership with the appointment of Jeffrey Blizard.
- Expansion into the European market with the launch of OviTex Inguinal for robotic and laparoscopic inguinal hernia repair.
- Optimization of existing talent through enhanced territory management and strategic resource allocation.
Challenges Ahead
- Potential impact from macroeconomic conditions, including recessionary concerns and increasing market interest rates.
- Risks related to demand for products due to changes in surgical procedure volumes, cybersecurity events, and hospital staffing shortages.
- Challenges in achieving or sustaining profitability.
- Potential for data from earlier studies not being replicated in later studies or indicative of future data.
- Risks associated with product development and manufacturing problems, capacity constraints, and supply chain disruptions.